Merck KGaA (OTCMKTS:MKGAF) Shares Gap Down – Should You Sell?

Shares of Merck KGaA (OTCMKTS:MKGAF) gapped down before the market opened on Tuesday . The stock had previously closed at $157.36, but opened at $148.4920. Merck KGaA shares last traded at $155.17, with a volume of 1,810 shares trading hands.

Merck KGaA Stock Performance

The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. The firm has a market cap of $20.41 billion, a price-to-earnings ratio of 24.11 and a beta of 0.96. The firm’s 50 day moving average price is $161.87 and its 200-day moving average price is $149.73.

Institutional Investors Weigh In On Merck KGaA

A number of institutional investors have recently bought and sold shares of the business. Elefante Mark B acquired a new stake in shares of Merck KGaA during the 2nd quarter valued at about $617,000. Ames National Corp acquired a new stake in shares of Merck KGaA in the second quarter valued at approximately $1,009,000. Notis McConarty Edward acquired a new stake in shares of Merck KGaA in the 2nd quarter valued at $1,304,000. North Star Asset Management Inc. bought a new stake in Merck KGaA during the 2nd quarter worth about $1,411,000. Finally, Pinnacle Holdings LLC bought a new stake in shares of Merck KGaA during the second quarter worth approximately $1,487,000. Institutional investors and hedge funds own 0.10% of the company’s stock.

About Merck KGaA

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The business serves customers in more than 60 countries through three operating sectors: Healthcare, Life Science and Electronics.

The Healthcare sector develops and markets prescription medicines and specialty therapies, with activities focused on areas including oncology, neurology and immunology, fertility, and endocrinology.